
Exclusive: Maze unveils their $191M pipeline, taking on Vertex and two long-sought conditions
More than two years after emerging from stealth mode with $191 million, a guild of prestigious scientific founders and support from some top-flight VCs, Maze Therapeutics is finally ready to unveil what they’ve been up to.
Maze CEO Jason Coloma walked Endpoints News through their de-stealthed pipeline Monday, showcasing three programs that are still early stage but progressed since the company’s 2019 launch. They include a new small molecule approach for the rare lysosomal disorder Pompe disease, a chronic kidney disease target that will put them in square competition with Vertex, and an ALS gene therapy that theoretically could be marketed for the entire patient population.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters